Treatment of chronic wounds: time for immunologic concern on drug design? by Kalavi, K. & Hazrati, S.M.
LETTER
Letter to the Editor
TREATMENT OF CHRONIC
WOUNDS: TIME FOR
IMMUNOLOGIC CONCERN ON
DRUG DESIGN?
Dear sirs
Professor Paul Davis has in his article (1)
considered advances and improvements in
immunology a major contribution towards
the therapeutics of diseases, especially wound
healing. We have been working along similar
lines for more than a decade in drug design and
have registered such drugs as patents (2–5).
Several well-known documents indicate
that cellular and molecular impairments of
immunologic origin are seen in chronic
wounds such as diabetic foot ulcers (DFUs) (6).
They are cytokine defects (mainly Th-1 medi-
ated), tendency to be associated with other
chronic diseases [tuberculosis in diabetes mel-
litus (DM) (7)], overexpression of matrix met-
alloproteinases (MMPs) (1,8) etc.
On the basis of worldwide literature, we have
been working on reverting or correcting the
defects responsible for DFU. We hypothesised
that the defect could be corrected by repair-
ing a biologic (immunologic based) mechanism
that has been assumed to be impaired in
patients with DFU and chronic wounds (6).
To prove such a hypothesis, we proposed that
factors such as decrease in macrophages and
fibroblasts and other cell recruitment impair-
ments and leukocyte function defects might
have been defective in these patients. Distur-
bances in pro-inflammatory and inflammatory
cytokines such as interleukin (IL)-1, tumour
necrosis factor (TNF)/alpha, and others such
as transforming growth factor alfa and beta
(TGF), interleukine 8 (IL-8), granulocyte mono-
cyte - colony stimulating factor (GM-CSF), and
interferon gamma (IFN/gamma) and many
other vital cells and molecules were all indica-
tive of an immunological defect in DFU. On
the other hand, based on the nature of the
abnormalities, we considered these patients to
be relatively immunocompromised, especially
with innate immune defects. We postulated
that many signs in these patients indicate that
they may lack proper cell immunity. Other
studies had also shown this to be true. The
immune defects included a lack of CD3+ T
lymphocytes, macrophage recruitment defect,
neutrophils and other phagocytic dysfunc-
tions. Disturbances in neutrophil function such
as failure of respiratory burst, INF/gamma,
interleukin 12 (IL-12), and deficiency of IL-1,
IL-2 receptors (IL-1 R, IL-2 Rs) and some other
critical factors led us to confirm that these
patients had innate cellular immunity failure,
as already discussed in our hypothesis (6). We
then suggested the possible importance of gain-
ing the effector functions of some critical cells
as phagocytes. In our subsequent works, we
postulated that this can be achieved with Th-1
cell activation as the mechanism of cellular and
molecular conduction. It could be concluded
that one of the defects in DFU might be the non-
specific immunity in its cellular and molecular
aspects. To achieve our goal in this direction we
proposed that Th-1 cells are the major gateway
through which the body may refresh itself. In
this stage, we used activators of Th-1 cells as
adjuvants. The non-specific immunity defects
were previously described in some reports.
Some interesting features observed apart from
the healing of non-healing wounds using the
available protocols are blockage of proteolytic
activity of enzymes associated with clot for-
mation as an appropriate mechanism for cells
and molecules necessary to act on wound heal-
ing, autolytic debridement of necrotic lesions
without use of surgical tools, control of infec-
tion without use of antibiotics and interestingly
control of interdigital fungal infection resistant
to all used antifungal agents.
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